Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14

作者：

Shimbashi, Reiko ^{[1
,2
]}

Suzuki, Motoi ^{[1
,2
]}

Chang, Bin ^{[1
]}

Watanabe, Hiroshi ^{[3
]}

Tanabe, Yoshinari ^{[4
]}

Kuronuma, Koji ^{[5
]}

Oshima, Kengo ^{[2
]}

Maruyama, Takaya ^{[6
]}

Takeda, Hiroaki ^{[7
]}

Kasahara, Kei ^{[8
]}

Fujita, Jiro ^{[9
]}

Nishi, Junichiro ^{[10
]}

Kubota, Tetsuya ^{[11
]}

Tanaka-Taya, Keiko ^{[1
]}

Matsui, Tamano ^{[1
]}

Sunagawa, Tomimasa ^{[1
]}

Oishi, Kazunori ^{[1
,12
]}

机构：

[1] Natl Inst Infect Dis, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan

[3] Kurume Univ, Sch Med, Fukuoka, Japan

[4] Niigata Prefectural Shibata Hosp, Niigata, Japan

[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan

[7] Yamagata Saisei Hosp, Yamagata, Japan

[8] Nara Med Univ, Nara, Japan

[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan

[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[11] Kochi Univ, Kochi Med Sch, Kochi, Japan

[12] Toyama Inst Hlth, Toyama, Japan

来源：

EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期

关键词：

PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;

D O I：

10.3201/eid2610.191531

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.

引用

页码：2378 / 2386

页数：9

共 50 条

[1] Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence
Niederman, Michael S.
Folaranmi, Temitope
Buchwald, Ulrike K.
Musey, Luwy
Cripps, Allan W.
Johnson, Kelly D.
EXPERT REVIEW OF VACCINES, 2021, 20 (03) : 243 - 255
[2] Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
Falkenhorst, Gerhard
Remschmidt, Cornelius
Harder, Thomas
Hummers-Pradier, Eva
Wichmann, Ole
Bogdan, Christian
PLOS ONE, 2017, 12 (01):
[3] Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales
Djennad, Abdelmajid
Ramsay, Mary E.
Pebody, Richard
Fry, Norman K.
Sheppard, Carmen
Ladhani, Shamez N.
Andrews, Nick J.
ECLINICALMEDICINE, 2018, 6 : 42 - 50
[4] Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark
Nielsen, Katrine Finderup
Nielsen, Lise Birk
Dalby, Tine
Lomholt, Frederikke Kristensen
Slotved, Hans-Christian
Fuursted, Kurt
Harboe, Zitta Barrella
Jorgensen, Charlotte Svaerke
Valentiner-Branth, Palle
EMERGING INFECTIOUS DISEASES, 2024, 30 (06) : 1164 - 1172
[5] Cost effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany
Jiang, Yiling
Gauthier, Aline
Annemans, Lieven
van der Linden, Mark
Nicolas-Spony, Laurence
Bresse, Xavier
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 645 - 660
[6] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Cho, Bo-Hyun
Stoecker, Charles
Link-Gelles, Ruth
Moore, Matthew R.
VACCINE, 2013, 31 (50) : 6011 - 6021
[7] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Malene, B. Mikkelsen
Oyvind, Husby
Tor, Molden
David, N. Mwaura
Jens, Olsen
Nanna, V. Kristensen
Jeffrey, Vietri
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
[8] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study
Lawrence, Hannah
Pick, Harry
Baskaran, Vadsala
Daniel, Priya
Rodrigo, Chamira
Ashton, Deborah
Edwards-Pritchard, Rochelle C.
Sheppard, Carmen
Eletu, Seyi D.
Litt, David
Fry, Norman K.
Rose, Samuel
Trotter, Caroline
McKeever, Tricia M.
Lim, Wei Shen
PLOS MEDICINE, 2020, 17 (10)
[9] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
Shiramoto, Masanari
Hanada, Ryuzo
Juergens, Christine
Shoji, Yasuko
Yoshida, Mizuki
Ballan, Barry
Cooper, David
Gruber, William C.
Scott, Daniel A.
Schmoele-Thoma, Beate
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
[10] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
Jiang, Yiling
Gauthier, Aline
Keeping, Sam
Carroll, Stuart
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927

← 1 2 3 4 5 →